Overactive bladder agents

Overactive bladder agents

Drug monograph · NCLEX study reference
Trade names	Ditropan, Detrol, Vesicare, Myrbetriq
Therapeutic class	Overactive bladder agent
Pharmacologic class	Antimuscarinics (oxybutynin, tolterodine, solifenacin); beta-3 agonist (mirabegron)
Onset / peak / duration	Symptom improvement over days; ER and transdermal forms available.
Half-life / level	Varies; no routine level.
Routes	PO (oral), Transdermal
High-alert (ISMP)	No
Black box warning	None
Antidote / reversal	Supportive care.
Pregnancy / lactation	Use only if clearly needed.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Overactive bladder agents (brand names Ditropan, Detrol, Vesicare, Myrbetriq) — Overactive bladder agent; Antimuscarinics (oxybutynin, tolterodine, solifenacin); beta-3 agonist (mirabegron).

Identification

• Therapeutic class: Overactive bladder agent.
• Pharmacologic class: Antimuscarinics (oxybutynin, tolterodine, solifenacin); beta-3 agonist (mirabegron).

Pharmacology

• Mechanism of action: Antimuscarinics relax the detrusor muscle by blocking acetylcholine; mirabegron relaxes the bladder by beta-3 stimulation (fewer anticholinergic effects).
• Onset / peak / duration: Symptom improvement over days; ER and transdermal forms available.
• Half-life / therapeutic level: Varies; no routine level.

Clinical use

• Indications: Overactive bladder (urgency, frequency, urge incontinence).
• Usual dose, route, frequency: PO daily or ER; oxybutynin also transdermal patch or gel.
• Maximum dose / adjustments: Reduce in renal and hepatic impairment; caution in elderly (anticholinergic cognitive effects).

Safety

• Contraindications: Urinary or gastric retention, narrow-angle glaucoma (antimuscarinics); uncontrolled hypertension (mirabegron).
• Black box warning: None.
• Interactions: Other anticholinergics (additive), CYP3A4 inhibitors; mirabegron raises some drug levels (digoxin, metoprolol).
• Pregnancy / lactation: Use only if clearly needed.
• High-alert: No.

Adverse effects

• Common side effects: Dry mouth, constipation, blurred vision, dizziness (antimuscarinics); hypertension (mirabegron).
• Serious effects to report: Urinary retention, confusion (especially elderly), acute glaucoma, severe hypertension (mirabegron).
• Antidote / reversal: Supportive care.

Nursing process

• Assessment before administration: Voiding pattern, glaucoma and retention history, blood pressure (mirabegron), cognition in elderly.
• Interventions during therapy: Monitor anticholinergic effects and bladder emptying; rotate oxybutynin patch sites.
• Monitor: Urinary symptoms, anticholinergic effects, blood pressure (mirabegron).
• Evaluation / expected outcome: Reduced urgency and frequency.

Patient teaching

• Patient teaching: Expect dry mouth and constipation; use sugar-free candy and fluids; avoid overheating; report inability to urinate.
• Notify provider if: Inability to urinate, confusion, eye pain, severe blood pressure rise.
• Administration tips: Swallow ER whole; rotate transdermal sites.